ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
09-01-2013
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
IBUPROFEN; METHOCARBAMOL
Dostopno od:
TEVA CANADA LIMITED
Koda artikla:
M03BA53
INN (mednarodno ime):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
Odmerek:
200MG; 500MG
Farmacevtska oblika:
TABLET
Sestava:
IBUPROFEN 200MG; METHOCARBAMOL 500MG
Pot uporabe:
ORAL
Enote v paketu:
18/40
Tip zastaranja:
OTC
Terapevtsko območje:
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Povzetek izdelek:
Active ingredient group (AIG) number: 0248961001; AHFS:
Status dovoljenje:
CANCELLED POST MARKET
Datum dovoljenje:
2021-08-12
Lastnosti izdelka
1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................
Preberite celoten dokument
